openPR Logo
Press release

Anti-Epileptic Drugs for Pediatrics Market Key Factors And Emerging Opportunities With Current Trends Analysis 2026 | Mylan N.V., Cephalon, Inc., GlaxoSmithKline plc, Janssen Pharmaceuticals, Novartis AG, Pfizer, Inc.

12-07-2020 12:33 PM CET | Health & Medicine


Anti-Epileptic Drugs for Pediatrics Market

Anti-Epileptic Drugs for Pediatrics Market

Anti-epileptic drugs for pediatric treatment are expected to experience visible shifts in terms of demand and adoption owing to factors such as rise in global prevalence of epilepsy, increasing healthcare spending and emergence of efficacious anti-epileptic drugs. Furthermore, co-morbidities associated with epilepsy such as depression and anxiety are on the rise and major players are investing in research and awareness programs for reduction of these co-morbidities along with epilepsy.

For instance, Sanofi, S.A. invests in awareness programs in regions such as Latin America, Africa, and Asia Pacific. The company offers products with price adjustments in these regions to increase the access to treatments. Moreover, product launches and approvals such as the Vimpat drug approvals in Europe and Japan for the treatment of partial onset seizures for UCB Pharma in 2016, are aiding the market growth.

Key players operating in the global Anti-epileptic Drugs for Pediatrics market include Mylan N.V., Cephalon, Inc., GlaxoSmithKline plc, Janssen Pharmaceuticals, Novartis AG, Pfizer, Inc., Sanofi S.A., UCB Pharma Limited, Sunovion Pharmaceuticals Limited, Valeant Pharmaceuticals International, Inc., Zynerba, Zogenix, and Insys Therapeutics.

Get PDF Brochure Of This Research Report @

Market Dynamics

Rising incidence of epilepsy is expected to drive the anti-epileptic drugs for pediatrics market growth over the forecast period. For instance, according to the American Academy of Pediatrics 2016, epilepsy is the most common childhood brain disorder in the U.S., and nearly 3 million Americans have this condition (450,000 of which are under the age of 17).

Major players are focusing on providing viable treatment options for patients suffering from refractory epilepsy or drug resistant epilepsy. The add-on or adjunctive therapies offer significant positive results with relatively less side effects. This, in turn, is expected to boost the market growth for anti-epileptic drugs. Some notable drugs in the pipeline such as Lyrica (Pregabalin), are showing potential therapeutic effects with fewer drug interactions, improved side effect profiles, and enhanced overall safety. These factors are expected to favour the market growth since most of the older treatments such as carbamazepine, valproate, and phenytoin, although effective, have very poor safety profiles and are not well-tolerated by pediatric patients.

Newer drug therapies with symptom specific indications are expected to boost market growth

Epilepsy is a highly prevalent disorder, and an estimated 50 million people worldwide are suffering from epilepsy, out of which almost 80% live in emerging economies as per the World Health Organization (WHO) 2019. According to the American Academy of Pediatrics, as of April 2017, epilepsy was estimated to affect 0.5% to 1% of children globally and is the most prevalent chronic condition of the central nervous system among children. According to Epilepsy Foundation, each year, around 150,000 new cases of epilepsy are reported in the U.S. and the rate of occurrence is high among young children and geriatric population. Furthermore, in 2015, the Society of Neuroscience stated that epilepsy affected around 10.5 million children worldwide, and the type and severity of the disorder varies significantly.

The incidence and prevalence of epilepsy in children appears to be lower in developed economies and highest in rural areas of emerging economies. This is mainly attributed to the presence of FDA-approved anti-epileptic drugs in developed economies and vast distribution channels ensuring higher accessibility to treatments. Scientific and technological advancements have led to the introduction of several medications in the past decade, which are used in combination in a personalized way by physicians for the treatment of pediatrics. Drugs approved by the U.S. Food & Drug Administration (FDA) include Phenytoin (Dilantin), Carbamazepine (Carbatrol), Divalproex Sodium (Depakote), and Ethosuximide (Zarontin).

Ask For Discount Before Purchasing This Business Report @

Global Anti-epileptic Drugs for Pediatrics Market - Restraints

However, lack of awareness regarding epilepsy and non-availability of medical facilities in poor and developing countries are some of the factors that are expected to hinder growth of the anti-epileptic drugs for pediatrics market.

Global Anti-epileptic Drugs for Pediatrics Market - Regional Insights

On the basis of region, the global anti-epileptic drugs for pediatrics market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America holds a dominant position in the global anti-epileptic drugs for pediatrics market owing to increasing number of regulatory approval for drugs. For instance, in 2018, Eisai Inc. received U.S. Food and Drug Administration (FDA) approval for its antiepileptic drug, FYCOMPA (perampanel) CIII, for monotherapy and adjunctive use in pediatric patients 4 years and older for the treatment of partial-onset seizures (POS) with or without secondarily generalized seizures.

Asia Pacific is the fastest growing region in the global anti-epileptic drugs for pediatrics market owing to increasing product launches. For instance, in 2019, GlaxoSmithKline plc. launched dispersible tablet formulation of Lamictal (lamotrigine dispersible tablet) for the treatment of epilepsy in China for pediatric patients.

Contact Us

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Anti-Epileptic Drugs for Pediatrics Market Key Factors And Emerging Opportunities With Current Trends Analysis 2026 | Mylan N.V., Cephalon, Inc., GlaxoSmithKline plc, Janssen Pharmaceuticals, Novartis AG, Pfizer, Inc. here

News-ID: 2203709 • Views: 273


Guidewires Market Industrial Output, Import & Export, Consumer Consumption and F …
Guidewires are flexible and thin tubes that guide a catheter for placement in the diseased organ. Guidewires are used to open the target vessels, cross lesions and provide definitive interventional therapy to patients. Guidewires are the crucial components of vascular intervention with indispensable uses in the field of minimally invasive surgeries due to its capacity of rendering precise and effective results. Guidewires are of several types as various clinical presentations
Big Data in Healthcare Market Growth Probability, Key Vendors and Future Scenari …
Big data in healthcare market revenue is expected to grow at lucrative rate over the forecast period primarily due to increased digitalization in industrial process. Digitization is transforming industrial processes, functions, products, and services. Advent of e-commerce has resulted in a sudden spurt in data being generated by various companies. Also, with decades of research and development activities across the healthcare industry, there is a large amount of data, referred
Cannabis Testing Service Market Application 2020- Industry Overview, Global Tren …
Cannabis market is highly influenced by rigorous legalization efforts, which are aiming for approval of cannabis for medicinal or recreational purpose. Various governments and regulatory authorities are taking efforts to legalize cannabis, owing to its medicinal benefits. Moreover, commercialization of cannabis-based products under the legalized standards require successful cannabis testing, which further results in lucrative growth opportunity for market players. Global Cannabis Testing Service Market - Competitive Landscape Key players operating in
Cervical Total Disc Replacement Devices Market Growth Projection, Cost Structure …
Cervical degenerative disc disease (DDD) is a clinical manifestation of spinal spondylitis that causes deterioration of the intervertebral discs of the cervical spine. Arm pain, weakness, and paresthesia associated with cervical radiculopathy are some symptoms associated with cervical degenerative disc disease (DDD). Cervical total disc replacement devices are used to treat the condition. These cervical total disc replacement devices are made of two materials; metal-on-metal and metal-on-biocompatible. Metal-on-metal articulation designs

All 5 Releases

More Releases for Drug

Biologics Drug Discovery Market
2019-2025 Biologics Drug Discovery Market Report with Depth Analysis The biologics drug discovery involves target identification, hit-to-lead stage, lead identification and optimization. The report presents a comprehensive overview, market size, shares, and growth opportunities of Biologics Drug Discovery market by product type, application, key manufacturers and key regions. Request For Free report Sample - Scope of the Report: Furthermore, Biologics Drug Discovery Market report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers or
Opioid Antagonist Drug Market
The global market has been prognosticated to earn demand from popular types of products such as external use, oral and applications such as household and hospital. The Company has made available another publication in its Healthcare archive of market intelligence reports, which is titled “Global Opioid Antagonist Drug Market Research Report 2018.” While the threat of substitutes and technological risks could have an unfavorable impact on the global market, potential
Drug and cosmetics
Drug and Cosmetics Conferences regards each one of the individuals to go to the On “Drug and Cosmetics” amidst October 17-October 18, 2018 in Toronto, Canada which melds brief keynote presentations, speaker talks, Exhibition, Symposia, Workshops. Drug and Cosmetics Congress is one of the meetings and conferences which will be visited by all the prestigious cosmetologists, Scientists, fiery inspectors, postgraduates, affiliations, business meanders under a solitary rooftop. DRug and cosmetics BLESSY MATHEW Program
Hepatitis Drug Market Hepatitis Drug Clinical Pipeline Report 2023
For Report Sample Contact: or +91-11-47067990 Report Table of Contents 1. Introduction to Hepatitis Disease 1.1 Prologue 1.1.1 History of Hepatitis 1.1.2 Causes of Hepatitis Disease 1.2 Types of Viruses which are Responsible for Hepatitis Disease 2. Global Prevalence of Hepatitis Infection 3. Available Drug Classes for Hepatitis Disease Treatment 3.1 Interferon Alfa Therapy 3.2 Protease Inhibitors Therapy 3.3 Polymerase
Microcapsules Drug Delivery Market Microcapsules Drug Delivery Sales Report 2022
For Report Sample Contact: or +91-11-47067990 Report Table of Contents 1. Indispensable Advent of Microcapsules 1.1 Trajectory of Microencapsulation 1.2 Why and wherefores for Microencapsulation 2. Characterization of Microcapsules 2.1 Composition of Microcapsules 2.2 Parameters Influencing Microcapsules 3. Engineering Technology of Microcapsules 3.1 Physical Manufacturing Technologies 3.2 Physicochemical and Chemical Technologies 4. Applicability of Microcapsules 4.1 Microcapsules in Pharmaceuticals 4.2 Microcapsules in Nutraceuticals
AstraZeneca’s NMOSD Drug receives orphan drug designation
April 18, 2017 Orphan Drug European Medicine Agency has Announced orphan drug designation for inebilizumab (earlier known as MEDI-551) developed by AstraZeneca PLC (AZN) for the treatment of neuromyelitis optica spectrum disorder (NMOSD). The drug has already received orphan drug status from US Food and Drug Administration (FDA). NMOSD, also called Devic’s disease, is a rare, autoimmune disorder of the central nervous system (CNS) that affects the functioning